SIRT1 and early-onset autosomal dominant Alzheimer disease: For example, specifically promoting HDAC1 activity with pharmacological SIRT1 activators or by increasing HDAC1 function via genetic overexpression can reduce DNA damage in mouse models of Alzheimer's disease and ischemia (Kim et al, 2008; Dobbin et al, 2013).